Indication
Prevention of graft-versus-host disease
Prevention of graft-versus-host disease refers to prophylactic intervention against a major systemic, immune-mediated complication that arises following allogeneic hematopoietic cell transplantation. Read more about Prevention of graft-versus-host disease
8 drugs 2 manufacturers
Drugs that treat it
Common Prevention of graft-versus-host disease therapies.
ORENCIA (abatacept/maltose)
ORENCIA (WITH MALTOSE) (abatacept/maltose)
TREGZI (allogeneic reg T cell immunotherapy, HSPC and T cell-vldq)
TREGZI HSPC AND TREG COMPONENT (allogeneic regulatory T cell immunother-vldq,HSPCs and Tregs)
TREGZI HSPC COMPONENT (allo reg T cell immuno-vldq, HSPCs (CD34+), step 1 of 3)
TREGZI TCON COMPONENT (allo reg T cell immuno-vldq, Tcons (CD3+), step 3 of 3)
TREGZI TREG COMPONENT (allo reg Tcell-vldq, Tregs (CD4+CD25+CD127-), step 2 of 3)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of graft-versus-host disease refers to prophylactic intervention against a major systemic, immune-mediated complication that arises following allogeneic hematopoietic cell transplantation.
In this clinical state, immunocompetent donor T lymphocytes recognize host minor or major histocompatibility antigens as foreign, triggering an inflammatory cascade and cytotoxic tissue destruction.
Prophylaxis aims to avert both acute and chronic forms of the disorder, which primarily target the skin, gastrointestinal tract, liver, and other epithelial or mucosal surfaces.
Pathophysiologically, preventive strategies seek to inhibit donor alloreactive T-cell activation, proliferation, or trafficking while mitigating systemic inflammatory damage and preserving engraftment and beneficial graft-versus-tumor responses.
- nih.gov
Prevention of graft-versus-host disease refers to prophylactic intervention against a major systemic, immune-mediated complication that arises following allogeneic hematopoietic cell transplantation Prophylaxis aims to avert both acute and chronic forms of the disorder, which primarily target the skin, gastrointestinal tract, liver, and other epithelial or mucosal surfaces Pathophysiologically, preventive strategies seek to inhibit donor alloreactive T-cell activation, proliferation, or traffick...
- nih.gov
Prevention of graft-versus-host disease refers to prophylactic intervention against a major systemic, immune-mediated complication that arises following allogeneic hematopoietic cell transplantation
- fda.gov
In this clinical state, immunocompetent donor T lymphocytes recognize host minor or major histocompatibility antigens as foreign, triggering an inflammatory cascade and cytotoxic tissue destruction Prophylaxis aims to avert both acute and chronic forms of the disorder, which primarily target the skin, gastrointestinal tract, liver, and other epithelial or mucosal surfaces
- nih.gov
In this clinical state, immunocompetent donor T lymphocytes recognize host minor or major histocompatibility antigens as foreign, triggering an inflammatory cascade and cytotoxic tissue destruction Pathophysiologically, preventive strategies seek to inhibit donor alloreactive T-cell activation, proliferation, or trafficking while mitigating systemic inflammatory damage and preserving engraftment and beneficial graft-versus-tumor responses
- fda.gov
Prophylaxis aims to avert both acute and chronic forms of the disorder, which primarily target the skin, gastrointestinal tract, liver, and other epithelial or mucosal surfaces
- nih.gov
Pathophysiologically, preventive strategies seek to inhibit donor alloreactive T-cell activation, proliferation, or trafficking while mitigating systemic inflammatory damage and preserving engraftment and beneficial graft-versus-tumor responses
Personalize your experience
Follow Prevention of graft-versus-host disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.